Literature DB >> 7533702

Pharmacokinetic profile of nifedipine GITS in hypertensive patients with chronic renal impairment.

R Schneider1, D Stolero, L Griffel, R Kobelt, E Brendel, A Iaina.   

Abstract

25 hypertensive patients with normal or impaired renal function underwent pharmacokinetic and safety studies after single and multiple dose administration of nifedipine GITS (Gastro-Intestinal Therapeutic System) 60mg tablets. Complete pharmacokinetic data were obtained from 23 of these patients. Blood pressure and heart rate changes were compatible with the known properties of the drug. Impaired renal function did not affect the maximum plasma concentrations or bioavailability of nifedipine after single or multiple dose administration of nifedipine GITS, nor was there any evidence of excessive drug accumulation in the presence of renal impairment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7533702     DOI: 10.2165/00003495-199400481-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  15 in total

1.  The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers.

Authors:  N M Debbas; S H Jackson; K Shah; S M Abrams; A Johnston; P Turner
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

2.  The trans-hepatic extraction of nifedipine.

Authors:  V F Challenor; D G Waller; A G Renwick; B S Gruchy; C F George
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

3.  Cytochrome P-450-catalyzed dehydrogenation of 1,4-dihydropyridines.

Authors:  F P Guengerich; R H Böcker
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

4.  Effect of food on nifedipine pharmacokinetics.

Authors:  D P Reitberg; S J Love; G T Quercia; M A Zinny
Journal:  Clin Pharmacol Ther       Date:  1987-07       Impact factor: 6.875

5.  Oxidative cleavage of carboxylic esters by cytochrome P-450.

Authors:  F P Guengerich
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

6.  Nifedipine: individual responses and concentration-effect relationships.

Authors:  R Donnelly; H L Elliott; P A Meredith; A W Kelman; J L Reid
Journal:  Hypertension       Date:  1988-10       Impact factor: 10.190

7.  Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects.

Authors:  T S Foster; S R Hamann; V R Richards; P J Bryant; D A Graves; R G McAllister
Journal:  J Clin Pharmacol       Date:  1983-04       Impact factor: 3.126

8.  Pharmacokinetic studies of nifedipine tablet. Correlation with antihypertensive effects.

Authors:  A M Taburet; E Singlas; J N Colin; O Banzet; M Thibonnier; P Corvol
Journal:  Hypertension       Date:  1983 Jul-Aug       Impact factor: 10.190

9.  Pharmacokinetics of amlodipine in renal impairment.

Authors:  G D Doyle; J Donohue; M Carmody; M Laher; H Greb; M Volz
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

10.  Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure.

Authors:  L van Bortel; R Böhm; J Mooij; P Schiffers; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

View more
  3 in total

Review 1.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

Review 2.  Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

3.  Effectiveness and Tolerability of Nifedipine GITS in Patients with Chronic Kidney Disease and Uncontrolled Hypertension: A Prospective, Multicenter, Observational Study (ADRENAL).

Authors:  Rong Lv; Jianghua Chen; Huamin Wang; Jijun Wang; Hong Cheng; Rong Li; Wei Li; Tao Zhang; Lixin Wei; Qinkai Chen; Jian Huang; Feng Yu; Shizhong Shen; Henglan Wu; Cuihong Liu; Fuyuan Hong; Jie Liu; Xiaoru Zhang; Hua Xiao; Wenbin Song
Journal:  Adv Ther       Date:  2021-07-30       Impact factor: 3.845

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.